366 related articles for article (PubMed ID: 10867550)
1. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.
Ricaurte GA; Yuan J; McCann UD
Neuropsychobiology; 2000; 42(1):5-10. PubMed ID: 10867550
[TBL] [Abstract][Full Text] [Related]
2. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.
McCann UD; Eligulashvili V; Ricaurte GA
Neuropsychobiology; 2000; 42(1):11-6. PubMed ID: 10867551
[TBL] [Abstract][Full Text] [Related]
3. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').
Ricaurte GA; McCann UD; Szabo Z; Scheffel U
Toxicol Lett; 2000 Mar; 112-113():143-6. PubMed ID: 10720723
[TBL] [Abstract][Full Text] [Related]
4. Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research.
Curran HV
Neuropsychobiology; 2000; 42(1):34-41. PubMed ID: 10867554
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
Baumann MH; Wang X; Rothman RB
Psychopharmacology (Berl); 2007 Jan; 189(4):407-24. PubMed ID: 16541247
[TBL] [Abstract][Full Text] [Related]
6. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
7. MDMA-induced serotonergic neurotoxicity enhances aggressiveness in low- but not high-aggressive rats.
Wallinga AE; ten Voorde AM; de Boer SF; Koolhaas JM; Buwalda B
Eur J Pharmacol; 2009 Sep; 618(1-3):22-7. PubMed ID: 19616536
[TBL] [Abstract][Full Text] [Related]
8. Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain.
Izco M; Orio L; O'Shea E; Colado MI
Psychopharmacology (Berl); 2007 Jan; 189(4):459-70. PubMed ID: 17047928
[TBL] [Abstract][Full Text] [Related]
9. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
10. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
11. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
Sanchez V; O'shea E; Saadat KS; Elliott JM; Colado MI; Green AR
J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging in human MDMA (Ecstasy) users.
Cowan RL; Roberts DM; Joers JM
Ann N Y Acad Sci; 2008 Oct; 1139():291-8. PubMed ID: 18991874
[TBL] [Abstract][Full Text] [Related]
13. "Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites.
Barbosa DJ; Capela JP; Silva R; Ferreira LM; Branco PS; Fernandes E; Bastos ML; Carvalho F
Arch Toxicol; 2014 Feb; 88(2):515-31. PubMed ID: 24177245
[TBL] [Abstract][Full Text] [Related]
14. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI.
Schouw ML; Gevers S; Caan MW; Majoie CB; Booij J; Nederveen AJ; Reneman L
Eur Neuropsychopharmacol; 2012 Aug; 22(8):537-45. PubMed ID: 22209360
[TBL] [Abstract][Full Text] [Related]
15. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).
Baumann MH; Rothman RB
Int Rev Neurobiol; 2009; 88():257-96. PubMed ID: 19897081
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.
Jones DC; Duvauchelle C; Ikegami A; Olsen CM; Lau SS; de la Torre R; Monks TJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):422-31. PubMed ID: 15634943
[TBL] [Abstract][Full Text] [Related]
17. A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.
Orio L; Llopis N; Torres E; Izco M; O'Shea E; Colado MI
Neurotox Res; 2010 Aug; 18(2):187-99. PubMed ID: 19777321
[TBL] [Abstract][Full Text] [Related]
18. Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine.
Hatzidimitriou G; Tsai EH; McCann UD; Ricaurte GA
Synapse; 2002 Apr; 44(1):51-7. PubMed ID: 11842446
[TBL] [Abstract][Full Text] [Related]
19. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
Vegting Y; Reneman L; Booij J
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.
McCann UD; Szabo Z; Scheffel U; Dannals RF; Ricaurte GA
Lancet; 1998 Oct; 352(9138):1433-7. PubMed ID: 9807990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
